Semaglutide News and Research

Latest Semaglutide News and Research

Study evaluates the difference in weight loss caused by two antidiabetic medications

Patients with Type 2 diabetes who were prescribed SGLT2 inhibitors lost more weight than patients who received GLP-1 receptor agonists, according to a University at Buffalo-led study.

2 Jul 2021

Vegan protein shakes may be viable alternatives to milk-based whey protein shakes

A study from the Centre for Nutraceuticals at the University of Westminster found that plant-based protein shakes may be potential viable alternatives to milk-based whey protein shakes, particularly in people with need of careful monitoring of glucose levels.

24 Jun 2021

Weight loss drug Wegovy approved by FDA

The U.S. Food and Drug Administration (FDA) has approved Wegovy (semaglutide) injection (2.4 mg once weekly) as a chronic weight management treatment in obese or overweight adults with a weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), when used along with calorie restriction and physical activity. Wegovy, is a more potent version of Novo Nordisk's diabetes drug semaglutide.

4 Jun 2021

Asthma patients can benefit from type 2 diabetes medication

Type 2 diabetes patients who also have asthma are benefitting from a diabetes medication, typically given to help the pancreas produce more insulin, that also improves asthma symptoms and may reduce lung and airway inflammation.

21 May 2021

Researchers reveal how to effectively achieve and maintain a healthy weight loss

Almost one in five Danes live with obesity, which may have serious health consequences. In the world's most recognized medical journal, Danish researchers now document how to effectively achieve and maintain a healthy weight loss.

6 May 2021

Hopkins Medicine endocrinologist publishes first clinical practice review on diabetes management

New medicines for people who have diabetes seem to pop up all the time. Drugs that help the body break down carbohydrates, drugs that increase excretion of glucose in the urine, drugs that help muscles respond to insulin and drugs that stimulate the pancreas to produce it - the list of pharmaceutical options to treat diabetes gets longer and longer.

7 Apr 2021

HCAs are a promising risk indicator of type 2 diabetes

A series of studies led by researchers from Hong Kong Baptist University have revealed that hyocholic acid and its derivatives (collectively known as HCAs), a component of bile acids that facilitate fat digestion, are a promising risk indicator of type 2 diabetes.

1 Apr 2021

Bariatric surgery can reduce the risk of obesity-related cancers, study shows

Bariatric surgery can significantly reduce the risk of cancer--and especially obesity-related cancers--by as much as half in certain individuals, according to a study by researchers at Rutgers Robert Wood Johnson Medical School's Center for Liver Diseases and Liver Masses.

26 Mar 2021

Semaglutide drug also helps diabetic patients lose body weight, shows study

A drug approved for diabetes has now been shown to also help patients with diabetes lose on average 10 percent of their body weight, UT Southwestern reports in a landmark international study.

3 Mar 2021

Study: Semaglutide drug promotes weight loss in patients with type 2 diabetes

Patients with type 2 diabetes that were treated with a weekly injection of the breakthrough drug Semaglutide were able to achieve an average weight loss of nearly 10kg, according to a new study published in The Lancet today.

3 Mar 2021

Study shows reliability and robustness of injectable anti-obesity medication

A second study of the injectable anti-obesity medication, semaglutide, has confirmed the large weight losses reported in a study earlier this month, establishing the reliability and robustness of this new drug.

24 Feb 2021

Study identifies new therapeutic targets for treatment of obesity and type 2 diabetes

The GIP receptor in the central nervous system plays a crucial role in the regulation of body weight and food intake.

10 Feb 2021

New drug combination improves blood glucose control and weight loss in mice

Scientists have shown that adding an experimental cancer drug to a widely used diabetes treatment improves blood glucose control and weight loss in mice, according to a study published today in eLife.

22 Dec 2020

Intensive interventions in type 2 diabetes reduce risk of cardiovascular autonomic neuropathy

Intensive interventions to reduce blood glucose and blood pressure levels in type 2 diabetes reduce the risk of developing cardiovascular autonomic neuropathy (CAN), a frequent but underdiagnosed complication of diabetes that can be life-threatening.

17 Dec 2020

Research uncovers novel anti-craving mechanism to treat cocaine relapse

Cocaine continues to be one of the most commonly abused illicit drugs in the United States. Pre-clinical literature suggests that targeting glucagon-like peptide-1 receptors (GLP-1Rs) in the brain may represent a novel approach to treating cocaine use disorder.

7 Dec 2020

Researchers elucidate the action mechanism of incretin-based drugs in treatment of diabetes

An international research group has clarified the action mechanism of incretin-based drugs in the treatment of diabetes.

26 Nov 2020

The Prospects of Semaglutide for Treatment of Type 2 Diabetes Patients

In this interview, News-Medical talks to Dr. Jan Westerink about recent studies into Novo Nordisk’s semaglutide and its potential benefits for Type 2 Diabetes patients, that he and Novo Nordisk collaborated on.

From Syneos Health 20 Nov 2020

Researchers find new link between incretin hormones and arteriosclerosis

Diabetes is currently treated using incretin hormones to reduce the risk of cardiovascular disease and other medical issues that the illness can trigger.

19 Nov 2020

A special issue on the emerging COVID-19 infection

Acta Pharmaceutica Sinica B publishes special issue on 'Research on Emerging COVID-19 (Target, Mechanism, and Therapeutics)' edited by Hai-Bin Luo, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China; Shilin Chen, Institute of Chinese Materia Medica, Beijing, China and Peiqing Liu, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.

29 Sep 2020

Newer Type 2 diabetes medications could reduce kidney, heart disease risks

Two newer groups of medications prescribed primarily for Type 2 diabetes treatment (SGLT2 inhibitors and GLP-1 receptor agonists) could significantly reduce risks associated with chronic kidney disease (CKD) and heart disease.

28 Sep 2020